Literature DB >> 25424768

The osteoblastic niche in the context of multiple myeloma.

Denise Toscani1, Marina Bolzoni, Fabrizio Accardi, Franco Aversa, Nicola Giuliani.   

Abstract

The osteoblastic niche has a critical role in the regulation of hemopoietic stem cell (HSC) quiescence and self-renewal and in the support of hematopoiesis. Several mechanisms are involved in the crosstalk between stem cells and osteoblasts, including soluble cytokines, adhesion molecules, and signal pathways such as the wingless-Int (Wnt), Notch, and parathyroid hormone pathways. According to the most recent evidence, there is an overlap between osteoblastic and perivascular niches that affects HSC function involving mesenchymal stromal and endothelial cells and a gradient of oxygen regulated by hypoxia inducible factor (HIF)-1α. Derived from plasma cells, multiple myeloma (MM) is a hematopoietic malignancy characterized by a peculiar dependency on the bone microenvironment. Quiescent MM cells may reside in the osteoblastic niche for protection from apoptotic stimuli; in turn, MM cells suppress osteoblast formation and function, leading to impairment of bone formation and the development of osteolytic lesions. Several recent studies have investigated the mechanisms involved in the relationship between osteoblasts and MM cells and identified potential therapeutic targets in the osteoblastic niche, including the HIF-1α, Runx2, and Wnt (both canonical and noncanonical) signaling pathways.
© 2014 New York Academy of Sciences.

Entities:  

Keywords:  Toscani, D., M. Bolzoni, F. Accardi, et al. 2014. The osteoblastic niche in the context of multiple myeloma. In “MARROW,” ed. by M. Zaidi. Ann. N.Y. Acad. Sci. xxxx: 1-18.; Wnt signaling; bone disease; myeloma; osteoblast; osteocyte

Mesh:

Year:  2014        PMID: 25424768     DOI: 10.1111/nyas.12578

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  22 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

Review 2.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone.

Authors:  Timothy N Trotter; Justin T Gibson; Tshering Lama Sherpa; Pramod S Gowda; Deniz Peker; Yang Yang
Journal:  Am J Pathol       Date:  2016-09-17       Impact factor: 4.307

4.  Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.

Authors:  Harmen van Andel; Zemin Ren; Iris Koopmans; Sander P J Joosten; Kinga A Kocemba; Wim de Lau; Marie José Kersten; Alexander M de Bruin; Jeroen E J Guikema; Hans Clevers; Marcel Spaargaren; Steven T Pals
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-27       Impact factor: 11.205

Review 5.  Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.

Authors:  Michael Heider; Katharina Nickel; Marion Högner; Florian Bassermann
Journal:  Oncol Res Treat       Date:  2021-11-08       Impact factor: 2.825

6.  Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production.

Authors:  Christopher Uhl; Themba Nyirenda; David S Siegel; Woo Y Lee; Jenny Zilberberg
Journal:  Heliyon       Date:  2022-03-24

7.  ILK promotes angiogenic activity of mesenchymal stem cells in multiple myeloma.

Authors:  Weipeng Zhao; Xiaoying Zhang; Li Zang; Pan Zhao; Yafang Chen; Xiaofang Wang
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

Review 8.  Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?

Authors:  Reinaldo Franqui-Machin; Erik B Wendlandt; Siegfried Janz; Fenghuang Zhan; Guido Tricot
Journal:  Oncotarget       Date:  2015-12-01

9.  SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.

Authors:  Roy Heusschen; Joséphine Muller; Marilène Binsfeld; Caroline Marty; Erwan Plougonven; Sophie Dubois; Nadia Mahli; Karen Moermans; Geert Carmeliet; Angélique Léonard; Frédéric Baron; Yves Beguin; Eline Menu; Martine Cohen-Solal; Jo Caers
Journal:  Oncotarget       Date:  2016-05-24

Review 10.  Spotlight on ixazomib: potential in the treatment of multiple myeloma.

Authors:  Barbara Muz; Rachel Nicole Ghazarian; Monica Ou; Micah John Luderer; Hubert Daniel Kusdono; Abdel Kareem Azab
Journal:  Drug Des Devel Ther       Date:  2016-01-11       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.